The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

A promising new study from the Knight Family DIAN-TU research group at Washington University School of Medicine has found that starting Alzheimer’s treatment years before symptoms begin could delay — ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients new hope through MUSC's SCAN program ...

A recent study of patients who developed bipolar disorder or depression later in life revealed that half had high ...

With promising drugs in the pipeline, we are on the cusp of "turning the tide" against Alzheimer's. But President Trump's plan to slash research spending could delay or halt progress for years, ...

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal ...

Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has said ...